Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[18F]Fluoro-d-Glucose Uptake in Prostate Cancer Mouse Xenografts

Molecular Imaging and Biology

Volumn 17, Issue 4, 2015, Pages 529-538

  Schlaepfer, Isabel R ^a   Glodé, L Michael ^a   Hitz, Carolyn A ^b   Pac, Colton T ^a   Boyle, Kristen E ^c   Maroni, Paul ^b   Deep, Gagan ^b   Agarwal, Rajesh ^b   Lucia, Scott M ^a   Cramer, Scott D ^a   Serkova, Natalie J ^a   Eckel, Robert H ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Beta oxidation; CPT1A; Etomoxir; Fatty acid; FDG PET; Glycolysis; Mitochondria

Indexed keywords

CARBON 13; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; COMPLEMENTARY DNA; ETOMOXIR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; SHORT HAIRPIN RNA; ANTIDIABETIC AGENT; CARNITINE PALMITOYLTRANSFERASE; EPOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; LIPID OXIDATION; MALE; MITOCHONDRION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; LIPID METABOLISM; METABOLISM; NUDE MOUSE; OXIDATION REDUCTION REACTION; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; EPOXY COMPOUNDS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HETEROGRAFTS; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MICE; MICE, NUDE; OXIDATION-REDUCTION; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84937525644     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0814-4     Document Type: Article

References (43)

1. Zadra G, Photopoulos C, Loda M (2013) The fat side of prostate cancer. Biochim Biophys Acta 1831(10):1518–1532
2. Swinnen JV, van Veldhoven PP, Timmermans L, De SE et al (2003) Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302:898–903
3. Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9:230–234
4. Jadvar H (2013) Imaging evaluation of prostate cancer with (18)F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 1:S5–10
5. Albers MJ, Bok R, Chen AP et al (2008) Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68:8607–8615
6. Nelson SJ, Kurhanewicz J, Vigneron DB et al (2013) Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(13)C]pyruvate. Sci Transl Med 5:198ra108
7. Jadvar H (2009) Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging 8:56–64
8. Hara T, Bansal A, DeGrado TR (2006) Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18 F]FDG in cultured prostate cancer cells. Nucl Med Biol 33:977–984
9. Abozguia K, Clarke K, Lee L, Frenneaux M (2006) Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 3:490–498
10. Fang YH, Piao L, Hong Z et al (2012) Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) 90:31–43
11. Schlaepfer IR, Rider L, Rodrigues LU et al (2014) Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther 13:2361–2371
12. Carracedo A, Cantley LC, Pandolfi PP (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13:227–232
13. Barclay WW, Woodruff RD, Hall MC, Cramer SD (2005) A system for studying epithelial–stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 146:13–18
14. Consitt LA, Bell JA, Koves TR et al (2010) Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals. Diabetes 59:1407–1415
15. Schlaepfer IR, Hitz CA, Gijon MA et al (2012) Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Mol Cell Endocrinol 363:111–121
16. Kominsky DJ, Klawitter J, Brown JL et al (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res 15:3442–3450
17. Morelli MP, Tentler JJ, Kulikowski GN et al (2012) Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res 18:1051–1062
18. Raina K, Ravichandran K, Rajamanickam S et al (2013) Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study. Cancer Prev Res (Phila) 6:40–50
19. Hinderling VB, Schrauwen P, Langhans W, Westerterp-Plantenga MS (2002) The effect of etomoxir on 24-h substrate oxidation and satiety in humans. Am J Clin Nutr 76:141–147
20. Schmidt-Schweda S, Holubarsch C (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99:27–35
21. Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D (2010) Metabolic modulation: a new therapeutic target in treatment of heart failure. Am. J. Ther 18:e197-e201
22. Keshari KR, Sai V, Wang ZJ et al (2013) Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18 F-FDG PET. J Nucl Med 54:922–928
23. Singh G, Lakkis CL, Laucirica R, Epner DE (1999) Regulation of prostate cancer cell division by glucose. J Cell Physiol 180:431–438
24. Rossi S, Graner E, Febbo P et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715
25. Rubin MA, Zhou M, Dhanasekaran SM et al (2002) Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662–1670
26. Pike LS, Smift AL, Croteau NJ et al (2011) Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 1807:726–734
27. Reilly PT, Mak TW (2012) Molecular pathways: tumor cells co-opt the brain-specific metabolism gene CPT1C to promote survival. Clin Cancer Res 18:5850–5855
28. Samudio I, Harmancey R, Fiegl M et al (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120:142–156
29. Andreassen OA, Zuber V, Thompson WK et al (2014) Shared common variants in prostate cancer and blood lipids. Int J Epidemiol 43:1205–1214
30. Crowe FL, Allen NE, Appleby PN et al (2008) Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case–control analysis nested within the European prospective investigation into cancer and nutrition. Am J Clin Nutr 88:1353–1363
31. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9:358–365
32. Tennakoon JB, Shi Y, Han JJ, et al. (2013) Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene 33:5251-5161
33. Ceccarelli SM, Chomienne O, Gubler M, Arduini A (2011) Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research. J Med Chem 54:3109–3152
34. Portilla D, Dai G, Peters JM et al (2000) Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 278:F667–F675
35. Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441:1–21
36. Ellis JM, Mentock SM, Depetrillo MA et al (2011) Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 31:1252–1262
37. Kaira K, Serizawa M, Koh Y, et al. (2013) Biological significance of F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 83:197-204
38. Pedersen PL (2007) Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr. 39:211–222
39. Andersen KF, Divilov V, Koziorowski J et al (2013) Antilipolytic drug boosts glucose metabolism in prostate cancer. Nucl Med Biol 40:524–528
40. Korenchuk S, Lehr JE, MClean L et al (2001) VCaP, a cell-based model system of human prostate cancer. In Vivo 15:163–168
41. van Bokhoven A, Varella-Garcia M, Korch C et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205–225
42. Jadvar H, Desai B, Ji L et al (2013) Baseline 18 F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 54:1195–1201
43. Liu Y (2014) Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer. Oncol Lett 7:2013–2018